🔴 Arcturus Therapeutics is trading 5% down today amid broader market weakness

Arcturus Therapeutics is trading at $13.63, down 5.22%, amid weaker broader-market sentiment.

• The Nasdaq Composite is down 0.78%, while the S&P 500 is down 0.44%.
• The company is scheduled to present ARCT-810 Phase 2 OTC-deficiency data at 4:30 p.m. ET on September 23, 2026.
• No new negative company-specific announcement or analyst downgrade was identified. Biotech is outperforming, so sector weakness does not explain the decline.